...less medical jargon in a 'Quick Glance' format!
ETANERCEPT SIDE EFFECTS; .. Entanercept (better known as Enbrel) is derived by introducing human DNA into Chinese hamster ovary cells and creating a genetically engineered protein.
Enbrel has been approved to treat:
.....moderate to severe rheumatoid arthritis
.....moderate to severe juvenile rheumatoid arthritis
.....chronic moderate to severe plaque psoriasis
redness, itching, pain, or swelling at the site of injection
bleeding or bruising at the site of injection
Some side effects can be serious. The following symptoms are uncommon, but if you experience any of them, call your doctor immediately:
fever, sore throat, chills, and other signs of infection
coughing, wheezing, or chest pain
hot, red, swollen area on the skin
difficulty breathing or swallowing
RISK OF INFECTIONS
Infections, including serious infections leading to hospitalization or death, have been observed in patients treated with ENBREL. Infections have included bacterial sepsis and tuberculosis. Patients should be educated about the symptoms of infection and closely monitored for signs and symptoms of infection during and after treatment with ENBREL. Patients who develop an infection should be evaluated for appropriate antimicrobial treatment and, in patients who develop a serious infection, ENBREL should be discontinued.
Tuberculosis has been observed in patients receiving TNF-blocking agents, including ENBREL. Tuberculosis may be due to reactivation of latent tuberculosis infection or to new infection. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with ENBREL than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including ENBREL. Patients should be evaluated for tuberculosis risk factors and be tested for latent tuberculosis infection prior to initiating ENBREL and during treatment. Treatment of latent tuberculosis infection should be initiated prior to therapy with ENBREL. Treatment of latent tuberculosis in patients with a reactive tuberculin test reduces the risk of tuberculosis reactivation in patients receiving TNF blockers. Some patients who tested negative for latent tuberculosis prior to receiving ENBREL have developed active tuberculosis. Physicians should monitor patients receiving ENBREL for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis infection.